Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: Protein context influences the degree of TAP-independent presentation

被引:57
作者
Wick, MJ [1 ]
Pfeifer, JD [1 ]
机构
[1] WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110
关键词
transporter associated with antigen processing (TAP); antigen processing and presentation; major histocompatibility complex class I molecule; ovalbumin;
D O I
10.1002/eji.1830261135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peritoneal macrophages from C57BL/6 mice process antigens from bacteria or coated on polystyrene beads for presentation by major histocompatibility complex (MHC) class I molecules. To investigate this antigen processing pathway peritoneal macrophages from homozygous TAP1(-/-) mice, which lack the transporter associated with antigen processing (TAP) and are defective in presenting endogenous antigens on MHC class I, were used. TAP1(-/-) or C57BL/6 macrophages were co-incubated with either bacteria or polystyrene beads containing the 257-264 epitope from ovalbumin [OVA(257-264)], which binds the mouse class I molecule K-b. The source of the OVA(257-264) epitope was either the Crl-OVA(257-264) (Crl-OVA) fusion protein, the maltose binding protein (MBP)-Crl-OVA fusion protein, native OVA or bacterial recombinant OVA (rOVA); Crl-OVA, MBP-Crl-OVA and rOVA were each expressed in bacteria, and Crl-OVA and MBP-Crl-OVA purified from bacterial lysates and native egg OVA were coated onto polystyrene beads. The data reveal that peritoneal macrophages from C57BL/6 and TAP1(-/-) mice can process bacteria expressing Crl-OVA, MBP-Crl-OVA and rOVA as well as beads coated with native OVA, purified Crl-OVA, and purified MBP-Crl-OVA and present OVA(257-264) for recognition by OVA(257-264)K-b-specific T hybridoma cells, albeit with different relative processing efficiencies. The processing efficiency of TAP1(-/-) macrophages co-incubated with bacteria or beads containing Crl-OVA or MBP-Crl-OVA was reduced approximately three to five times compared to C57BL/6 macrophages, but OVA(257-264) was presented 100 times less efficiently when the source of OVA(257-264) was full-length OVA. Chloroquine inhibition studies showed a differential requirement for acidic compartments in C57BL/6 versus TAP1(-/-) macrophages, which also depended upon the source of the OVA (257-264) epitope (Crl-OVA versus full-length OVA). These data suggest that TAP1(-/-) and C57BL/6 macrophages may process Crl-OVA and full-length OVA in different cellular compartments and that the protein context of the OVA(257-264) epitope influences the extent of TAP-independent processing for MHC class I presentation.
引用
收藏
页码:2790 / 2799
页数:10
相关论文
共 44 条
[1]  
ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443
[2]   TAP1-INDEPENDENT LOADING OF CLASS-I MOLECULES BY EXOGENOUS VIRAL-PROTEINS [J].
BACHMANN, MF ;
OXENIUS, A ;
PIRCHER, H ;
HENGARTNER, H ;
ASHTONRICHARDT, PA ;
TONEGAWA, S ;
ZINKERNAGEL, RM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) :1739-1743
[3]  
BOHM W, 1995, J IMMUNOL, V155, P3313
[4]   CLASS-II-RESTRICTED PRESENTATION OF AN ENDOGENOUSLY DERIVED IMMUNODOMINANT T-CELL DETERMINANT OF HEN EGG LYSOZYME [J].
BROOKS, A ;
HARTLEY, S ;
KJERNIELSEN, L ;
PERERA, J ;
GOODNOW, CC ;
BASTEN, A ;
MCCLUSKEY, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3290-3294
[5]   CLASS-I-RESTRICTED PROCESSING AND PRESENTATION OF EXOGENOUS CELL-ASSOCIATED ANTIGEN INVIVO [J].
CARBONE, FR ;
BEVAN, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (02) :377-387
[6]  
DASGUPTA JD, 1988, J IMMUNOL, V141, P2577
[7]   EFFICIENT PROCESSING OF AN ANTIGENIC SEQUENCE FOR PRESENTATION BY MHC CLASS-I MOLECULES DEPENDS ON ITS NEIGHBORING RESIDUES IN THE PROTEIN [J].
DELVAL, M ;
SCHLICHT, HJ ;
RUPPERT, T ;
REDDEHASE, MJ ;
KOSZINOWSKI, UH .
CELL, 1991, 66 (06) :1145-1153
[8]   ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES [J].
FALK, K ;
ROTZSCHKE, O ;
STEVANOVIC, S ;
JUNG, G ;
RAMMENSEE, HG .
NATURE, 1991, 351 (6324) :290-296
[9]  
GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155
[10]  
HARDING CV, 1994, J IMMUNOL, V153, P4925